G. Mel’nichenko, V. Peterkova, L. Savel'eva, N. Zubkova
An open, comparative, randomized study of orlistat in the combined treatment of obesity in adolescents with metabolic syndrome (IIIb phase) was held. Objective: to evaluate the efficacy and safety of the orlistat in adolescents 12-17 years with high risk of cardiovascular disease and type 2 diabetes. The study included 60 adolescents with obesity and metabolic syndrome. The main group (n=30) followed a hypocaloric diet and aerobic exercises and took orlistat 120 mg 3 times daily with meals, the control (n=30) group was only on the non-drug therapy. During the study the anthropometric parameters, lipid, carbohydrate metabolism, blood pressure were evaluated. All comparisons were performed as two-way, with the critical level of significance ≤ 0,05. Results: After 6 months therapy of orlistat 68% of adolescents achieved clinically meaningful weight loss, that led to the improvement of metabolic parameters. On therapy body fat decreased by -6600.00 g [-7912.00, -2350.00] in the control group, respectively -2235.50 g [-4700, 00; 667.00] (p=0.011). Orlistat was well tolerated by patients. Most adverse events (9 of 13 in the intervention group) were mild and can be attributed to the expected adverse reactions. Conclusion: The study demonstrated clinically significant efficacy (compared with the control group), combined with good safety records of its use in adolescents 12-17 years old with obesity and metabolic disorders.
一项开放、比较、随机研究奥利司他联合治疗青少年代谢综合征(IIIb期)肥胖。目的:评价奥利司他在12-17岁心血管疾病和2型糖尿病高危青少年中的疗效和安全性。该研究包括60名患有肥胖和代谢综合征的青少年。主要组(n=30)在低热量饮食和有氧运动的基础上，口服奥利司他120 mg，每日3次，随餐服用，对照组(n=30)只进行非药物治疗。在研究期间，测量了人体测量参数、脂质、碳水化合物代谢和血压。所有比较均采用双向比较，显著性临界水平≤0.05。结果:经6个月奥利司他治疗后，68%的青少年实现了有临床意义的体重减轻，代谢参数得到改善。治疗后，对照组体脂下降-6600.00 g[-7912.00， -2350.00]，分别为-2235.50 g [- 4700000];667.00 (p = 0.011)。奥利司他在患者中耐受性良好。大多数不良事件(干预组13例中有9例)是轻微的，可归因于预期的不良反应。结论:该研究显示出临床显著的疗效(与对照组相比)，并结合其在12-17岁肥胖和代谢紊乱青少年中使用的良好安全性记录。
{"title":"Evaluation of effectiveness of orlistat in complexed obesity treatment in teenagers with metabolic syndrome","authors":"G. Mel’nichenko, V. Peterkova, L. Savel'eva, N. Zubkova","doi":"10.14341/2071-8713-5302","DOIUrl":"https://doi.org/10.14341/2071-8713-5302","url":null,"abstract":"An open, comparative, randomized study of orlistat in the combined treatment of obesity in adolescents with metabolic syndrome\u0000(IIIb phase) was held. Objective: to evaluate the efficacy and safety of the orlistat in adolescents 12-17 years with high risk of cardiovascular\u0000disease and type 2 diabetes. The study included 60 adolescents with obesity and metabolic syndrome. The main group (n=30)\u0000followed a hypocaloric diet and aerobic exercises and took orlistat 120 mg 3 times daily with meals, the control (n=30) group was only\u0000on the non-drug therapy. During the study the anthropometric parameters, lipid, carbohydrate metabolism, blood pressure were evaluated.\u0000All comparisons were performed as two-way, with the critical level of significance ≤ 0,05. Results: After 6 months therapy of orlistat\u000068% of adolescents achieved clinically meaningful weight loss, that led to the improvement of metabolic parameters. On therapy body\u0000fat decreased by -6600.00 g [-7912.00, -2350.00] in the control group, respectively -2235.50 g [-4700, 00; 667.00] (p=0.011). Orlistat\u0000was well tolerated by patients. Most adverse events (9 of 13 in the intervention group) were mild and can be attributed to the expected\u0000adverse reactions. Conclusion: The study demonstrated clinically significant efficacy (compared with the control group), combined with\u0000good safety records of its use in adolescents 12-17 years old with obesity and metabolic disorders.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67044628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Rankin, P. Tennant, K. Stothard, M. Bythell, C. Summerbell, R. Bell
{"title":"Maternal body mass index and congenital anomaly risk: a cohort stu","authors":"J. Rankin, P. Tennant, K. Stothard, M. Bythell, C. Summerbell, R. Bell","doi":"10.14341/2071-8713-5197","DOIUrl":"https://doi.org/10.14341/2071-8713-5197","url":null,"abstract":"","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67045011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christina Wang, Eberhard Nieschlag, S. Ronald, Hermann M. Behre, J. H. Wayne, Justine Louis, M. Jean, Jean-Jacques Legros, Bruno Lunenfeld, Alvaro Morales, E. M. John, Claude C. Schulman, M. T. Ian, W. Weidner, C. W. W. Frederick
{"title":"Rekomendatsii ISA, ISSAM, EAU, EAA i ASA: diagnostika, lechenie i monitorirovanie vozrastnogogipogonadizma u muzhchin","authors":"Christina Wang, Eberhard Nieschlag, S. Ronald, Hermann M. Behre, J. H. Wayne, Justine Louis, M. Jean, Jean-Jacques Legros, Bruno Lunenfeld, Alvaro Morales, E. M. John, Claude C. Schulman, M. T. Ian, W. Weidner, C. W. W. Frederick","doi":"10.14341/2071-8713-5211","DOIUrl":"https://doi.org/10.14341/2071-8713-5211","url":null,"abstract":"","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67044545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Susanne Tan, L. Bechmann, S. Benson, T. Dietz, S. Eichner, S. Hahn, O. Janssen, H. Lahner, G. Gerken, K. Mann, A. Canbay
{"title":"Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome","authors":"Susanne Tan, L. Bechmann, S. Benson, T. Dietz, S. Eichner, S. Hahn, O. Janssen, H. Lahner, G. Gerken, K. Mann, A. Canbay","doi":"10.14341/2071-8713-5214","DOIUrl":"https://doi.org/10.14341/2071-8713-5214","url":null,"abstract":"","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67044548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This article shows a significant efficacy and safety data of original drug Xenical in complex treatment of overweight and obesity patients. It is emphasized that this data describe properties of original Xenical, but not generics. The generic drug Orsoten has completely different physicochemical characteristics comparing to Xenical, this differences may lead to increase in allergic reactions and increase of frequency and intensity of side effects.
{"title":"Ksenikal v kompleksnom lechenii patsientovs izbytochnoy massoy tela i ozhireniem","authors":"M. L. Maksimov","doi":"10.14341/2071-8713-5276","DOIUrl":"https://doi.org/10.14341/2071-8713-5276","url":null,"abstract":"This article shows a significant efficacy and safety data of original drug Xenical in complex treatment of overweight and obesity\u0000patients. It is emphasized that this data describe properties of original Xenical, but not generics. The generic drug Orsoten has completely\u0000different physicochemical characteristics comparing to Xenical, this differences may lead to increase in allergic reactions and increase of\u0000frequency and intensity of side effects.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67044610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There are several pseudogenerics of Meridia® and Xenical®. Lindaxa®, registered in Russia, as a generic of Meridia®, can be at a disadvantage to a brand on cost-quality ratio.
{"title":"Dzheneriki pri lechenii ozhireniya","authors":"M. Y. Drobizhev","doi":"10.14341/2071-8713-5275","DOIUrl":"https://doi.org/10.14341/2071-8713-5275","url":null,"abstract":"There are several pseudogenerics of Meridia® and Xenical®. Lindaxa®, registered in Russia, as a generic of Meridia®, can be at\u0000a disadvantage to a brand on cost-quality ratio.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67044607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Savel'eva, R. Rozhivanov, B. O. Shurdumova, V. Fadeev
Objective: to evaluate the preavalence and characteristics of hypogonadism in obese man. Research and Methods: Thestudy was performed in 31 obese man (aged 33 [22;44], BMI 40 [34,4;44,0]. Measurements during the study: chemistry panel, testosteroa and LH levels, immunoreactive insulin, HOMA index calculation. Statistically significant difference w as considered as p < 0,05. Results. Hypogonadism preavalence was 80,6%. The hypogonadism prevalence and testosterone level was more depended on age and obesity but less on duration. 100 % risk of hypogonadism w as observed in heavily obese patients. There w as no increase of LH levels. In man with low testosterone lev els HOMA index w as significantly higher со mpared to healthy subjects. Conclusion: The prevalence of normogonadotropic hypogonadism in obese men is extremely high and it represents an evidence of functional disorder of hypophyseal gonadal system. Thedecrease of testosterone levels is age-coinciding, but it is more pronounced in obese nan.
{"title":"Normogonadotropic hypogonadism in men with obesity","authors":"L. Savel'eva, R. Rozhivanov, B. O. Shurdumova, V. Fadeev","doi":"10.14341/2071-8713-5243","DOIUrl":"https://doi.org/10.14341/2071-8713-5243","url":null,"abstract":"Objective: to evaluate the preavalence and characteristics of hypogonadism in obese man. Research and Methods: Thestudy was performed in 31 obese man (aged 33 [22;44], BMI 40 [34,4;44,0]. Measurements during the study: chemistry panel, testosteroa and LH levels, immunoreactive insulin, HOMA index calculation. Statistically significant difference w as considered as p < 0,05. Results. Hypogonadism preavalence was 80,6%. The hypogonadism prevalence and testosterone level was more depended on age and obesity but less on duration. 100 % risk of hypogonadism w as observed in heavily obese patients. There w as no increase of LH levels. In man with low testosterone lev els HOMA index w as significantly higher со mpared to healthy subjects. Conclusion: The prevalence of normogonadotropic hypogonadism in obese men is extremely high and it represents an evidence of functional disorder of hypophyseal gonadal system. Thedecrease of testosterone levels is age-coinciding, but it is more pronounced in obese nan.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67044562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Research objective: to study obesity among 10541 patients in therapeutic, neurologik and cardiologikal practices in 29 cities of the Russian Federation from St.-Petersburg to Vladivostok (COMPASS program). All patients are divided on two groups: with obesity (average BMI=33,7+4,1 kg/m2), and without this disease (average BMI=24,4+3,0 kg/m2). Groups were compared under demographic characteristics; features of a medical route; somatic and mental state. 20% from all patients in mentioned practices in various cities of Russia have obesity. Patients with obesity are predominantly women (middle age 54,0+12,0 year). For these patients low social and economic status (with low educational level, absence of employment, loneliness etc.) are characteristic. Patients with obesity are more often observe in cardiological practice. They suffer from cardiovascular diseases and type 2 diabetes. The hypothesis about obesity formation within mental disorders (depression, food addiction - dependence on food) is presented. Possibility of treatment of patients with the help of sibutramine is discussed.
{"title":"Ozhirenie sredi bol'nykh, obrativshikhsya za meditsinskoy pomoshch'yu (dannye krupnogo otechestvennogo epidemiologicheskogo issledovaniya)","authors":"M. Y. Drobizhev","doi":"10.14341/2071-8713-5316","DOIUrl":"https://doi.org/10.14341/2071-8713-5316","url":null,"abstract":"Research objective: to study obesity among 10541 patients in therapeutic, neurologik and cardiologikal practices in 29 cities of the Russian Federation from St.-Petersburg to Vladivostok (COMPASS program). All patients are divided on two groups: with obesity (average BMI=33,7+4,1 kg/m2), and without this disease (average BMI=24,4+3,0 kg/m2). Groups were compared under demographic characteristics; features of a medical route; somatic and mental state. 20% from all patients in mentioned practices in various cities of Russia have obesity. Patients with obesity are predominantly women (middle age 54,0+12,0 year). For these patients low social and economic status (with low educational level, absence of employment, loneliness etc.) are characteristic. Patients with obesity are more often observe in cardiological practice. They suffer from cardiovascular diseases and type 2 diabetes. The hypothesis about obesity formation within mental disorders (depression, food addiction - dependence on food) is presented. Possibility of treatment of patients with the help of sibutramine is discussed.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67044685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rol' metabolicheskikh i gemodinamicheskikh narusheniy u muzhchin s metabolicheskim sindromom v razvitii infertil'nosti i erektil'noy disfunktsii","authors":"A. Mkrtumyan, E. Romanova, A. Oranskaya","doi":"10.14341/2071-8713-5225","DOIUrl":"https://doi.org/10.14341/2071-8713-5225","url":null,"abstract":"","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67044555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The importance of studying the psychological aspects of nutrition diet is, perhaps, the most commonly used words in the lexicon of Endocrinology and Diabetology and most unpleasant - for patients with diabetes mellitus (DM). Any restrictions on certain aspects of nutrition in patients with diabetes create a negative attitude to the disease, since they require non-established habits and tastes, a significant change in lifestyle, often - constant "struggle" with gusto. And if type 1 diabetes decrease dietary restrictions for patient education - the so-called liberalized diet - allows much to make life easier to patient without compromising compensation diabetes [3, 11], the rules for type 2 diabetes, especially in combination with obesity, are fundamentally based on constraints.
{"title":"Psychological aspects of diet therapy in type 2 diabetes mellitus","authors":"E. Starostina","doi":"10.14341/OMET200827-10","DOIUrl":"https://doi.org/10.14341/OMET200827-10","url":null,"abstract":"The importance of studying the psychological aspects of nutrition diet is, perhaps, the most commonly used words in the lexicon of Endocrinology and Diabetology and most unpleasant - for patients with diabetes mellitus (DM). Any restrictions on certain aspects of nutrition in patients with diabetes create a negative attitude to the disease, since they require non-established habits and tastes, a significant change in lifestyle, often - constant \"struggle\" with gusto. And if type 1 diabetes decrease dietary restrictions for patient education - the so-called liberalized diet - allows much to make life easier to patient without compromising compensation diabetes [3, 11], the rules for type 2 diabetes, especially in combination with obesity, are fundamentally based on constraints.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67047449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：